- Home
- / Oncternal Therapeutics
Oncternal Therapeutics
Stock Price
$1.5
2024-10-29
Market Capitalization
$4.5 M
2024-10-29
Revenue
$785 K
FY, 2023
Oncternal Therapeutics Summary
Company Summary
- Overview
- Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapies. It offers Zilovertamab, a monoclonal antibody designed to inhibit the function of ROR1; ONCT-808, an autologous CAR-T cell therapy that targets ROR1; ONCT-534, a monotherapy treatment for patients with advanced prostate cancer; etc.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Sonoma, CA, US | view all locations
- Website
- https://www.oncternal.com/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
1 location detected
Sonoma, CA HQ
United States
12230 El Camino Real #230
Oncternal Therapeutics Financials
Summary Financials
- Revenue (Q3, 2024)
- $494.0K
- Net income (Q3, 2024)
- ($8.5M)
- Cash (Q3, 2024)
- $13.1M
- EBIT (Q3, 2024)
- ($8.7M)
- Enterprise value
- ($8.4M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026